#### FORM 4

C/O VERTEX PHARMACEUTICALS

**INCORPORATED** 130 WAVERLY ST.

(Street)

(City)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|             |      |       |

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP                           |
|--|--|
| obligations may continue. See  |  |
| 1 t  | Filed nursuant to Costion 10(a) of the Cosurities Fusiones Act of 1004 |

| OMB AP      | ROVAL    |
|-------------|----------|
| OMB Number: | 3235-028 |

37 Estimated average burden hours per response: 0.5

> 10% Owner Other (specify

> > trust.(4)

| Instruction 1(b).                                       | Filed | pursuant to Section 16(a) of the Securities Exchange Act of 1934   |   |   | nours per respo        | onse:                       |
|---|-------|--|---|---|------------------------|-----------------------------|
|   |       | or Section 30(h) of the Investment Company Act of 1940   |   |   |                        |                             |
| 1. Name and Address of Reporting Person* BOGER JOSHUA S |       | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]   |   | ationship of R<br>all applicabl<br>Director | Reporting Perso<br>le) | n(s) to Issuer<br>10% Owner |
| (Last) (First) (Mid                                     | ldle) | WILL AND THE STATE OF THE STATE |   | Officer (gives)                             | e title                | Other (spec<br>below)       |
| C/O MEDTEN DILADMA CELITICALE                           |       | 3. Date of Earliest Transaction (Month/Day/Year)   | 1 |   |                        |                             |

10/03/2012 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)

#### Form filed by One Reporting Person CAMBRIDGE MA 02139 Form filed by More than One Reporting Person (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of 6. Ownership Form: Direct 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 7. Nature Execution Date, Transaction Securities Beneficially of Indirect (Month/Day/Year) if anv Code (Instr. (D) or Indirect **Beneficial** (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership (Instr. 4) Reported (A) or (D) Transaction(s) Code ٧ Amount Price (Instr. 3 and 4) 10/03/2012 636,895 Common Stock M 4,000 A \$15.6 D **S**<sup>(1)</sup> \$57.74(2)(3) Common Stock 10/03/2012 4,000 D 632,895 D Common Stock 13,286 Ī 401(k) Common Stock Common Stock 300,000 I held in

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   |     |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D)   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Employee<br>Stock<br>Option<br>(right to<br>buy)    | \$15.6  | 10/03/2012                                 |   | M                            |   |     | 4,000 | (5)  | 01/17/2013         | Common<br>Stock  | 4,000                                  | \$0.00  | 50,951   | D  |  |

#### **Explanation of Responses:**

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$57.74 (range \$57.56 to \$57.93).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Common stock held in grantor retained annuity trusts.
- 5. Fully vested.

# Remarks:

Valerie L. Andrews, Attorney-

10/04/2012

In-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.